| |  Online-Ressource |
|---|
| Verfasst von: | Kockerols, Camille [VerfasserIn]  |
|---|
| | Valk, Peter J. M. [VerfasserIn] |
|---|
| | Janssen, Jeroen J. W. M. [VerfasserIn] |
|---|
| | Hogenbirk, Pauline [VerfasserIn] |
|---|
| | Cornelissen, Jan J. [VerfasserIn] |
|---|
| | Saußele, Susanne [VerfasserIn] |
|---|
| | Spiess, Birgit [VerfasserIn] |
|---|
| | Perusini, Maria Agustina [VerfasserIn] |
|---|
| | Kim, Dennis [VerfasserIn] |
|---|
| | Westerweel, Peter E. [VerfasserIn] |
|---|
| Titel: | Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients |
|---|
| Verf.angabe: | Camille Kockerols, Peter J.M. Valk, Jeroen J.W.M. Janssen, Pauline Hogenbirk, Jan J. Cornelissen, Susanne Saussele, Birgit Spiess, Maria Agustina Perusini, Dennis Kim, Peter E. Westerweel |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | November 2024 |
|---|
| Umfang: | 8 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online veröffentlicht: 12. Juli 2024 ; Gesehen am 25.11.2024 |
|---|
| Titel Quelle: | Enthalten in: European journal of haematology |
|---|
| Ort Quelle: | Oxford : Wiley-Blackwell, 1987 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 113(2024), 5, Seite 606-613 |
|---|
| ISSN Quelle: | 1600-0609 |
|---|
| Abstract: | Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth of molecular response measured by BCR::ABL1 digital PCR (dPCR). The aim of this study was to validate a previously described prediction cutoff of 0.0023%IS and to assess the value of dPCR for treatment-free remission (TFR) prediction in relation to other clinical parameters. A droplet-based dPCR assay assessed BCR::ABL1 %IS prior to TKI discontinuation. The primary endpoint was molecular recurrence (MolR) by 36 months. A total of 186 patients from Canada, Germany, and the Netherlands were included. In patients with a first TKI discontinuation attempt (n = 163), a BCR::ABL1 dPCR < and ≥0.0023%IS had a MolR probability of 33% and 70%, respectively. Patients treated less than 6 years with a BCR::ABL1 dPCR <0.0023%IS had a MolR probability of 31%. After correction for treatment duration, both high dPCR value and the use of imatinib (vs. second-generation TKI) were significantly associated with a higher risk of MolR (HR of 3.66, 95%CI 2.06-6.51, p < .001; and 2.85, 95%CI 1.25-6.46, p = .013, respectively). BCR::ABL1 dPCR was not associated with TFR outcome after second TKI discontinuation, however, with the limitation of a small number of patients analyzed (n = 23). In conclusion, BCR::ABL1 digital PCR based on the cutoff of 0.0023%IS is a valuable predictive tool to identify CML patients with a high probability of TFR success after first TKI discontinuation, including patients treated for less than 6 years. |
|---|
| DOI: | doi:10.1111/ejh.14271 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1111/ejh.14271 |
|---|
| | kostenfrei: Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.14271 |
|---|
| | DOI: https://doi.org/10.1111/ejh.14271 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | BCR::ABL1 digital PCR |
|---|
| | chronic myeloid leukemia |
|---|
| | treatment-free remission |
|---|
| | tyrosine kinase inhibitor discontinuation |
|---|
| K10plus-PPN: | 1909449229 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients / Kockerols, Camille [VerfasserIn]; November 2024 (Online-Ressource)
